Mizuho Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $82
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $76 to $82.

February 16, 2024 | 11:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh maintains a Buy rating on Intra-Cellular Therapies and raises the price target from $76 to $82.
The upgrade in price target by a reputable analyst like Graig Suvannavejh from Mizuho is a strong positive signal for Intra-Cellular Therapies. It suggests a bullish outlook on the stock's future performance, likely due to anticipated operational successes or financial improvements. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100